<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742066</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 07-2-115</org_study_id>
    <nct_id>NCT00742066</nct_id>
  </id_info>
  <brief_title>Role of AT1-receptor Blockers in Insulin-induced Vasodilation.</brief_title>
  <official_title>Insulin-induced Microvascular Activity in Patients With Essential Hypertension: a Possible Role for Angiotensin II AT1-receptor Blockers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the
      insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II
      AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2.
      Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular
      effects in normotensive control subjects?
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional recruitment of capillaries in the skin</measure>
    <time_frame>July 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>perfused capillary density in the nailfold</measure>
    <time_frame>July 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium- (in)dependent vasodilatation of finger skin microcirculation</measure>
    <time_frame>July 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Density of arterioles, capillaries and venules in the bulbar conjunctiva.</measure>
    <time_frame>July 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of arterioles and venules in the bulbar conjunctiva</measure>
    <time_frame>July 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypertension</condition>
  <condition>Insulin Resistance</condition>
  <condition>Microcirculation</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irbesartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Felodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Single dose 600mg orally</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Aprovel C09CA04</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felodipine</intervention_name>
    <description>single dose 10mg Felodipine ER</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Plendil C08CA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose tablet orally</description>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        hypertensive subjects:

          1. 18-60 years

          2. Caucasian

          3. untreated hypertension &gt;140/90mmHg.

        normotensive subjects:

          1. 18-60 years

          2. Caucasian

          3. Blood pressure &lt;140/90 mmHg.

        Exclusion Criteria:

          1. Obesity (BMI&gt;27kg/m2)

          2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease,
             heart failure)

          3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA

          4. Smoking

          5. Alcohol use &gt;4U/day

          6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids,
             NNSAIDs)

          7. Pregnancy

          8. Wearing contact lenses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CDA Stehouwer, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Univeristy Hospital Maastricht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>P.O. Box 5800</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <last_update_submitted>March 16, 2011</last_update_submitted>
  <last_update_submitted_qc>March 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. CDA Stehouwer</name_title>
    <organization>University Hospital Maastricht</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Angiotensin II receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Felodipine</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

